CalciMedica, Inc. - CALC STOCK NEWS

Welcome to our dedicated page for CalciMedica news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CalciMedica stock.

CalciMedica, Inc. (Nasdaq: CALC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule drugs for treating autoimmune disorders, organ transplant rejection, and other immune diseases. The company's primary focus is on developing therapies for life-threatening inflammatory diseases with a high unmet need. Utilizing its proprietary technology, CalciMedica targets the inhibition of calcium release-activated calcium (CRAC) channels. This approach is designed to modulate the immune response and protect against tissue cell injury, offering therapeutic benefits for diseases with no approved therapies.

CalciMedica's lead product candidate, Auxora™, is an intravenous-formulated CRAC channel inhibitor that has shown promising results in multiple clinical trials. The company is currently conducting several significant studies:

• CARPO Trial: A Phase 2b international, randomized, double-blind, placebo-controlled, dose-ranging trial aimed at establishing Auxora's efficacy in treating acute pancreatitis with accompanying systemic inflammatory response syndrome (SIRS). The trial has successfully enrolled 216 patients, with topline data expected in the second quarter of 2024.
• CRSPA Study: An investigator-sponsored Phase 1/2 trial focusing on pediatric patients with acute lymphoblastic leukemia (ALL) experiencing asparaginase-induced pancreatic toxicity (AIPT). This study aims to define an optimal pediatric dose for Auxora and is expected to provide additional data by the second half of 2024.
• KOURAGE Trial: A Phase 2 trial targeting patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF). This randomized, double-blind, placebo-controlled study plans to evaluate 150 patients, with data anticipated in 2025.

CalciMedica has also secured substantial funding through a securities purchase agreement, raising up to $55 million in gross proceeds. This financing will support ongoing and planned clinical trials, bringing the company closer to achieving its goal of providing effective treatments for critically ill patients.

Recent achievements include the presentation of positive Phase 1/2 CRSPA study results at the 65th Annual American Society of Hematology Meeting and the clearance of an Investigational New Drug (IND) application by the FDA for the KOURAGE trial. Additionally, the company has engaged in a private placement financing, ensuring continued financial health and the ability to pursue pivotal clinical trials.

Founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, CalciMedica is headquartered in La Jolla, CA. For more information, visit www.calcimedica.com.